Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last $2.25 USD
Change Today +0.01 / 0.45%
Volume 139.2K
As of 8:10 PM 04/1/15 All times are local (Market data is delayed by at least 15 minutes).

arqule inc (ARQL) Snapshot

Open
$2.22
Previous Close
$2.24
Day High
$2.25
Day Low
$2.19
52 Week High
03/9/15 - $2.50
52 Week Low
10/15/14 - $1.04
Market Cap
141.3M
Average Volume 10 Days
449.7K
EPS TTM
$-0.36
Shares Outstanding
62.8M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for ARQULE INC (ARQL)

arqule inc (ARQL) Related Businessweek News

No Related Businessweek News Found

arqule inc (ARQL) Details

ArQule, Inc., a clinical-stage biotechnology company, researches and develops cancer therapeutics. Its lead product candidate tivantinib is an inhibitor of the c-Met receptor tyrosine kinase and its biological pathway, which is in Phase 3 clinical trial for the treatment of non-small cell lung and liver cancer; and Phase 2 clinical trial for the treatment of colorectal cancer. The company’s early clinical-stage products include ARQ 092, an inhibitor of the Akt protein kinase; ARQ 087, a multi-kinase inhibitor with pan-fibroblast growth factor receptor activity; ARQ 761, a NQ01 inhibitor; ARQ 621, an inhibitor of the Eg5 kinesin motor protein; and ARQ 736, an inhibitor of the RAF kinases. It has partnership agreement with Daiichi Sankyo Co., Ltd. and Kyowa Hakko Kirin Co., Ltd. for implementing a clinical development program designed to realize the potential of tivantinib as a single agent; and in combination with other anti-cancer therapies in various disease indications. In addition, the company has research collaboration with Daiichi Sankyo Co., Ltd. to discover therapeutic compounds that selectively inhibit certain kinases in the field of oncology based on its ArQule Kinase Inhibitor Platform (AKIP) technology. ArQule, Inc. was founded in 1993 and is headquartered in Woburn, Massachusetts.

40 Employees
Last Reported Date: 03/4/15
Founded in 1993

arqule inc (ARQL) Top Compensated Officers

Chief Executive Officer and Director
Total Annual Compensation: $489.3K
President, Principal Financial Officer, Chief...
Total Annual Compensation: $413.9K
Chief Medical Officer and Senior Vice Preside...
Total Annual Compensation: $380.3K
Compensation as of Fiscal Year 2013.

arqule inc (ARQL) Key Developments

ArQule Inc. Reports Unaudited Consolidated Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2014; Provides Earnings Guidance for the Full Year 2015

ArQule Inc. reported unaudited consolidated earnings results for the fourth quarter and full year ended December 31, 2014. For the quarter, research and development revenue was $3,015,000 against $2,275,000 a year ago. Loss from operations was $4,111,000 against $6,170,000 a year ago. Net loss was $3,512,000 or $0.06 per basic and diluted share against $5,956,000 or $0.10 per basic and diluted share a year ago. The $4.6 million revenue decrease in 2014 is primarily due to revenue decreases of $2.2 million from its Daiichi Sankyo tivantinib program due to a change in the estimated development period; $1.2 million from its Daiichi Sankyo 092 agreement that ended in June 2013; and $1.7 million of other revenue from a onetime research project that was completed in 2013. These decreases were partially offset by lower contra-revenue of $0.5 million. For the full year, research and development revenue was $11,254,000 against $15,914,000 a year ago. Loss from operations was $24,270,000 against $25,127,000 a year ago. Net loss was $23,391,000 or $0.37 per basic and diluted share against $24,600,000 or $0.39 per basic and diluted share a year ago. For the full year of 2015, the company expects net use of cash to range between $26 million and $29 million. Revenues are expected to range between $8 million and $10 million. Net loss is expected to range between $18 million and $21 million, and net loss per share to range between $0.29 and $0.33 for the year. The company expects to end 2015 with between $32 million and $35 million in cash and marketable securities.

ArQule Inc. to Report Q4, 2014 Results on Mar 04, 2015

ArQule Inc. announced that they will report Q4, 2014 results at 9:00 AM, US Eastern Standard Time on Mar 04, 2015

ArQule Inc., Q4 2014 Earnings Call, Mar 04, 2015

ArQule Inc., Q4 2014 Earnings Call, Mar 04, 2015

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
ARQL:US $2.25 USD +0.01

ARQL Competitors

Market data is delayed at least 15 minutes.

Company Last Change
AVEO Pharmaceuticals Inc $1.52 USD +0.07
CrystalGenomics Inc 11,800 KRW 0.00
Curis Inc $2.35 USD -0.05
Cytokinetics Inc $7.00 USD +0.22
Rigel Pharmaceuticals Inc $3.75 USD +0.18
View Industry Companies
 

Industry Analysis

ARQL

Industry Average

Valuation ARQL Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 12.5x
Price/Book 3.5x
Price/Cash Flow NM Not Meaningful
TEV/Sales 7.2x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact ARQULE INC, please visit www.arqule.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.